Nobuyuki Kanematsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nobuyuki Kanematsu has a total of 658 co-authors. Here are the top co-authors by number of shared publications:
H. Yoshida
33 shared publications- Junji Haba
SOKENDAI The Graduate University for Advanced Studies) 240-0193 15 Hayama
32 shared publications K. Amako
30 shared publicationsF. Takasaki
28 shared publicationsS. Mori
28 shared publicationsT. Nakamura
28 shared publications
Latest Publications
- 13 November 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (21) , 215037
Three-dimensional computational evaluation of water-to-air mass stopping power ratio for therapeutic helium-, carbon-, oxygen-, and neon-ion beams and its application to patient-specific quality assurance
Objective. Current dosimetry protocols recommend a constant water-to-air mass stopping power ratio, s w,air , of 1.126 with an uncertainty of ±1.5% for light ions, irrespective of ion species and energy. This study aims to develop a computational framework to calculate three-dimensional s w,air distributions of helium-, carbon-, oxygen-, and neon-ion beams for patient specific quality assurance (PSQA), and to systematically investigate spatial variations in s w,air under clinically relevant conditions. Approach. A computational framework was developed to calculate three-dimensional s w,air distributions based on the Bragg-Gray approximation, together with three-dimensional dose distributions for treatment planning. The framework was validated against published datasets for a mono-energetic carbon-ion beam. Treatment plans were generated using helium-, carbon-, oxygen-, and neon-ion beams for rectangular targets with varying spread-out Bragg peak (SOBP) widths and depths, as well as for bone and soft tissue, head and neck, and ocular cases. The corresponding s w,air distributions were calculated in a water phantom and compared with the recommended value of 1.126. Main Results. The mean s w,air within the target increased for shallower targets with narrower SOBP widths. For all ion species, s w,air increased toward the distal end of the SOBP, with larger variations observed for heavier ion species. In neon-ion irradiations for shallow targets, s w,air occasionally exceeded the ±1.5% uncertainty range in a limited region near the distal end of the SOBP. In all other cases, s w,air remained within the uncertainty range. Similar trends were observed in clinical cases. Based on these results, when considering the mean s w,air within the target, the suitable fixed values were 1.128 for carbon and oxygen ions and 1.129 for helium and neon ions. Significance . The proposed computational framework enables three-dimensional, plan-specific evaluation of s w,air and provides a practical approach for improving the dosimetric accuracy in charged-particle therapy with helium, carbon, oxygen, and neon ions, especially for PSQA.
- 13 November 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (21) , 215037
Three-dimensional computational evaluation of water-to-air mass stopping power ratio for therapeutic helium-, carbon-, oxygen-, and neon-ion beams and its application to patient-specific quality assurance
Objective. Current dosimetry protocols recommend a constant water-to-air mass stopping power ratio, s w,air , of 1.126 with an uncertainty of ±1.5% for light ions, irrespective of ion species and energy. This study aims to develop a computational framework to calculate three-dimensional s w,air distributions of helium-, carbon-, oxygen-, and neon-ion beams for patient specific quality assurance (PSQA), and to systematically investigate spatial variations in s w,air under clinically relevant conditions. Approach. A computational framework was developed to calculate three-dimensional s w,air distributions based on the Bragg-Gray approximation, together with three-dimensional dose distributions for treatment planning. The framework was validated against published datasets for a mono-energetic carbon-ion beam. Treatment plans were generated using helium-, carbon-, oxygen-, and neon-ion beams for rectangular targets with varying spread-out Bragg peak (SOBP) widths and depths, as well as for bone and soft tissue, head and neck, and ocular cases. The corresponding s w,air distributions were calculated in a water phantom and compared with the recommended value of 1.126. Main Results. The mean s w,air within the target increased for shallower targets with narrower SOBP widths. For all ion species, s w,air increased toward the distal end of the SOBP, with larger variations observed for heavier ion species. In neon-ion irradiations for shallow targets, s w,air occasionally exceeded the ±1.5% uncertainty range in a limited region near the distal end of the SOBP. In all other cases, s w,air remained within the uncertainty range. Similar trends were observed in clinical cases. Based on these results, when considering the mean s w,air within the target, the suitable fixed values were 1.128 for carbon and oxygen ions and 1.129 for helium and neon ions. Significance . The proposed computational framework enables three-dimensional, plan-specific evaluation of s w,air and provides a practical approach for improving the dosimetric accuracy in charged-particle therapy with helium, carbon, oxygen, and neon ions, especially for PSQA.
- Open Access
- 11 February 2026
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 19 (1) , 8-9
Selection of Radiological Physics and Technology Awards 2025
- 11 February 2026
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 19 (1) , 8-9
Open AccessSelection of Radiological Physics and Technology Awards 2025
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (3)
Robustness of LET d -optimized multi-ion therapy against range and setup uncertainties: evaluation and enhancement with carbon-, oxygen-, and neon-ion beams
Objective: The LET trilemma—an inherent conflict between target dose homogeneity, range robustness, and high dose-averaged linear energy transfer (LET d )—poses a major challenge in treatment optimization. To ensure accurate beam delivery in multi-ion therapy, this study evaluated the effects of range and setup uncertainties on LET d -optimized treatment plans and explored strategies to overcome this trilemma, framed within the phase I LET d escalation trial for head and neck cancers. Approach: Six head and neck cancer patients representing diverse tumors were selected. Multi-ion therapy plans using carbon-, oxygen-, and neon-ion beams were optimized to achieve a target LET d of 90 keV/μm (the final LET d level of the phase I trial). These plans were recalculated to incorporate uncertainties arising from stopping power ratio conversion and random daily setup variations across the 16 fractions, and their combined effects on the dose and LET d distributions were evaluated. Additionally, to explore strategies to increase plan robustness, five modified plans were evaluated for one patient identified as particularly susceptible to these uncertainties. Main results: Range uncertainty was the dominant contributor to degraded plan quality in multi-ion therapy, substantially outweighing setup uncertainty. A small, centrally located tumor was most susceptible, exhibiting dose inhomogeneity of approximately 11%, while LET d variations were approximately 3 keV/μm. The most effective strategy involved replacing the original carbon−oxygen combination with oxygen ions for two beam ports, reducing dose inhomogeneity by more than 7% while maintaining normal tissue sparing adjacent to the target. Significance: Optimization toward achieving higher LET d makes treatment plans susceptible to range uncertainty, leading to dose degradation within small, deep-seated tumors. Employing heavier ions is an effective strategy to overcome this challenge, enabling robust target coverage by leveraging their inherently higher LET d while sparing normal tissues. These findings provide a key rationale for ion selection in the design of robust multi-ion therapy.
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (3)
Robustness of LET d -optimized multi-ion therapy against range and setup uncertainties: evaluation and enhancement with carbon-, oxygen-, and neon-ion beams
Objective: The LET trilemma—an inherent conflict between target dose homogeneity, range robustness, and high dose-averaged linear energy transfer (LET d )—poses a major challenge in treatment optimization. To ensure accurate beam delivery in multi-ion therapy, this study evaluated the effects of range and setup uncertainties on LET d -optimized treatment plans and explored strategies to overcome this trilemma, framed within the phase I LET d escalation trial for head and neck cancers. Approach: Six head and neck cancer patients representing diverse tumors were selected. Multi-ion therapy plans using carbon-, oxygen-, and neon-ion beams were optimized to achieve a target LET d of 90 keV/μm (the final LET d level of the phase I trial). These plans were recalculated to incorporate uncertainties arising from stopping power ratio conversion and random daily setup variations across the 16 fractions, and their combined effects on the dose and LET d distributions were evaluated. Additionally, to explore strategies to increase plan robustness, five modified plans were evaluated for one patient identified as particularly susceptible to these uncertainties. Main results: Range uncertainty was the dominant contributor to degraded plan quality in multi-ion therapy, substantially outweighing setup uncertainty. A small, centrally located tumor was most susceptible, exhibiting dose inhomogeneity of approximately 11%, while LET d variations were approximately 3 keV/μm. The most effective strategy involved replacing the original carbon−oxygen combination with oxygen ions for two beam ports, reducing dose inhomogeneity by more than 7% while maintaining normal tissue sparing adjacent to the target. Significance: Optimization toward achieving higher LET d makes treatment plans susceptible to range uncertainty, leading to dose degradation within small, deep-seated tumors. Employing heavier ions is an effective strategy to overcome this challenge, enabling robust target coverage by leveraging their inherently higher LET d while sparing normal tissues. These findings provide a key rationale for ion selection in the design of robust multi-ion therapy.
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (1) , 01TR03
Neon ion radiotherapy: physics and biology
Neon ion ( 20 Ne) beam radiotherapy was one of the primary particle therapy candidates investigated during the clinical trials beginning in the 1970s at the Lawrence Berkely National Laboratory (LBNL), which shut down in the early 1990s. Currently, therapeutic neon ion beams are available at only one clinical facility worldwide, the National Institutes for Quantum Science and Technology (QST) in Chiba, Japan. Recently, neon ion beams were commissioned at QST Hospital as part of the first clinical multi-ion therapy (MIT) program, which aims to improve clinical outcomes by escalating higher linear energy transfer (LET) radiation in the tumor for treating therapy-resistant disease. With the advancement of high-precision scanning delivery techniques, neon ion treatments in the present day could be delivered more safely and with greater precision compared to the first and only clinical application decades prior at LBNL using passive scattering technology. Despite their promising results, preclinical investigations of neon ions are scarce outside of Japan and further independent studies are needed. Clinically, neon ion therapy may offer benefits in treating certain malignancies by escalating LET in the tumor, but its limited availability and high costs restrict its current use and adoption. Studies have shown that 20 Ne or multi-ion mixtures ( 4 He, 12 C, 16 O and/or 20 Ne) can provide larger degrees of freedom in optimization of dose, LET and relative biological effectiveness, otherwise unattainable with other single ion techniques. Neon ion beams are under investigation in the ongoing MIT clinical trials which will establish their broader applicability. In this review, the technology, physics, radiobiology, and potential clinical applications of neon ion beams are outlined. The status of therapeutic neon ion beams is provided while discussing future research and clinical directions, including technological development of novel particle therapy delivery techniques, such as multi-ion, mini-beam, arc, and ultra-high dose rate.
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (1) , 01TR03
Neon ion radiotherapy: physics and biology
Neon ion ( 20 Ne) beam radiotherapy was one of the primary particle therapy candidates investigated during the clinical trials beginning in the 1970s at the Lawrence Berkely National Laboratory (LBNL), which shut down in the early 1990s. Currently, therapeutic neon ion beams are available at only one clinical facility worldwide, the National Institutes for Quantum Science and Technology (QST) in Chiba, Japan. Recently, neon ion beams were commissioned at QST Hospital as part of the first clinical multi-ion therapy (MIT) program, which aims to improve clinical outcomes by escalating higher linear energy transfer (LET) radiation in the tumor for treating therapy-resistant disease. With the advancement of high-precision scanning delivery techniques, neon ion treatments in the present day could be delivered more safely and with greater precision compared to the first and only clinical application decades prior at LBNL using passive scattering technology. Despite their promising results, preclinical investigations of neon ions are scarce outside of Japan and further independent studies are needed. Clinically, neon ion therapy may offer benefits in treating certain malignancies by escalating LET in the tumor, but its limited availability and high costs restrict its current use and adoption. Studies have shown that 20 Ne or multi-ion mixtures ( 4 He, 12 C, 16 O and/or 20 Ne) can provide larger degrees of freedom in optimization of dose, LET and relative biological effectiveness, otherwise unattainable with other single ion techniques. Neon ion beams are under investigation in the ongoing MIT clinical trials which will establish their broader applicability. In this review, the technology, physics, radiobiology, and potential clinical applications of neon ion beams are outlined. The status of therapeutic neon ion beams is provided while discussing future research and clinical directions, including technological development of novel particle therapy delivery techniques, such as multi-ion, mini-beam, arc, and ultra-high dose rate.
- 2 December 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (23) , 235029
Evaluation of diamond and silicon detectors for linear energy transfer measurements of therapeutic helium, carbon, oxygen, and neon ion beams
Objective. Diamond and silicon detectors are increasingly popular tools for dose-averaged linear energy transfer (LET) in water L ¯ w measurements of therapeutic ion beams. The LET measured in detector materials is linearly scaled to the LET in water using a calibration coefficient based on the mass stopping power ratio (MSPR) of water to detector material at a specific particle energy. However, because the MSPR varies with particle energy, this conventional conversion method introduces L ¯ w errors. This study aims to quantify these errors for helium, carbon, oxygen, and neon ion beams and to propose a conversion method to reduce them. Approach. Rectangular targets were defined within a water phantom, and treatment plans were generated using helium, carbon, oxygen, and neon ion beams to achieve uniform dose distributions within the targets. The L ¯ w distributions delivered to the water phantom by the ion beams were calculated. The dose-averaged LET distributions in water L ¯ w, DM and L ¯ w, Si measured by diamond and silicon detectors based on the conventional conversion method were also calculated. Furthermore, a conversion method incorporating the particle-energy dependence of the MSPR was applied to the silicon detector outputs to derive dose-averaged LET distributions L ¯ w, Si _ prop . These distributions were then compared with the corresponding L ¯ w distributions. Main results. Given the high water equivalence of diamond, L ¯ w, DM distributions agreed with the L ¯ w distributions within 1% accuracy across all ion beams. In contrast, the poor water equivalence of silicon resulted in L ¯ w, Si distributions up to 10.5% lower than the L ¯ w distributions within the targets. However, when the energy-dependent MSPR-based conversion method was employed, the L ¯ w, Si _ prop distributions obtained with the silicon detectors showed good agreement with the L ¯ w distributions across all ion beams. Significance. The energy-dependent MSPR-based conversion method is highly effective for silicon detectors, despite their inherently poor water-equivalence properties. Silicon detectors can be used as accurate L ¯ w detectors in ion-beam radiotherapy.
- 2 December 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (23) , 235029
Evaluation of diamond and silicon detectors for linear energy transfer measurements of therapeutic helium, carbon, oxygen, and neon ion beams
Objective. Diamond and silicon detectors are increasingly popular tools for dose-averaged linear energy transfer (LET) in water L ¯ w measurements of therapeutic ion beams. The LET measured in detector materials is linearly scaled to the LET in water using a calibration coefficient based on the mass stopping power ratio (MSPR) of water to detector material at a specific particle energy. However, because the MSPR varies with particle energy, this conventional conversion method introduces L ¯ w errors. This study aims to quantify these errors for helium, carbon, oxygen, and neon ion beams and to propose a conversion method to reduce them. Approach. Rectangular targets were defined within a water phantom, and treatment plans were generated using helium, carbon, oxygen, and neon ion beams to achieve uniform dose distributions within the targets. The L ¯ w distributions delivered to the water phantom by the ion beams were calculated. The dose-averaged LET distributions in water L ¯ w, DM and L ¯ w, Si measured by diamond and silicon detectors based on the conventional conversion method were also calculated. Furthermore, a conversion method incorporating the particle-energy dependence of the MSPR was applied to the silicon detector outputs to derive dose-averaged LET distributions L ¯ w, Si _ prop . These distributions were then compared with the corresponding L ¯ w distributions. Main results. Given the high water equivalence of diamond, L ¯ w, DM distributions agreed with the L ¯ w distributions within 1% accuracy across all ion beams. In contrast, the poor water equivalence of silicon resulted in L ¯ w, Si distributions up to 10.5% lower than the L ¯ w distributions within the targets. However, when the energy-dependent MSPR-based conversion method was employed, the L ¯ w, Si _ prop distributions obtained with the silicon detectors showed good agreement with the L ¯ w distributions across all ion beams. Significance. The energy-dependent MSPR-based conversion method is highly effective for silicon detectors, despite their inherently poor water-equivalence properties. Silicon detectors can be used as accurate L ¯ w detectors in ion-beam radiotherapy.
- Open Access
- 8 February 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 33, 100727
Optimizing the dose-averaged linear energy transfer for the dominant intraprostatic lesions in high-risk localized prostate cancer patients
- 8 February 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 33, 100727
Open AccessOptimizing the dose-averaged linear energy transfer for the dominant intraprostatic lesions in high-risk localized prostate cancer patients
- Open Access
- 6 February 2025
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 18 (1) , 1-2
Selection of Radiological Physics and Technology Awards 2024
- 6 February 2025
- Published by Springer Nature in Radiological Physics and Technology
- Vol. 18 (1) , 1-2
Open AccessSelection of Radiological Physics and Technology Awards 2024
- 16 January 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (2) , 025008
Effects of intra-tumoral cellular heterogeneity of oxygen partial pressure on biological effectiveness of hydrogen-, helium-, carbon-, oxygen-, and neon-ion beams
Objective. The tumor microenvironment characterized by heterogeneously organized vasculatures causes intra-tumoral heterogeneity of oxygen partial pressure p at the cellular level, which cannot be measured by current imaging techniques. The intra-tumoral cellular p heterogeneity may lead to a reduction of therapeutic effects of radiation. The purpose of this study was to investigate the effects of the heterogeneity on biological effectiveness of H-, He-, C-, O-, and Ne-ion beams for different oxygenation levels, prescribed dose levels, and cell types. Approach. The intra-tumoral cellular p distributions were simulated with a numerical tumor model for average oxygen pressures p ¯ t ranging from 2.5 to 15 mmHg. The relative biological effectiveness (RBE)-weighted dose distributions of 3–15 Gy prescribed doses were planned for a cuboid target with the five ion species for constant p ¯ t values. Radiosensitivities of human salivary gland tumor (HSG) and Chinese hamster ovary (CHO) cells were investigated. The planned dose distributions were then recalculated by taking the p heterogeneity into account. Main results. As p ¯ t decreased and prescribed dose increased, the biological effectiveness of the ion beams decreased due to the p heterogeneity. The reduction in biological effectiveness was pronounced for lighter H- and He-ion beams compared to heavier C-, O-, and Ne-ion beams. The RBE-weighted dose in the target for HSG (CHO) cells decreased by 41.2% (44.3%) for the H-ion beam, while it decreased by 16.7% (14.7%) for the Ne-ion beam at a prescribed dose of 15 Gy under a p ¯ t of 2.5 mmHg. Significance. The intra-tumoral cellular p heterogeneity causes a significant reduction in biological effectiveness of ion beams. These effects should be considered in estimation of therapeutic outcomes.
- 16 January 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (2) , 025008
Effects of intra-tumoral cellular heterogeneity of oxygen partial pressure on biological effectiveness of hydrogen-, helium-, carbon-, oxygen-, and neon-ion beams
Objective. The tumor microenvironment characterized by heterogeneously organized vasculatures causes intra-tumoral heterogeneity of oxygen partial pressure p at the cellular level, which cannot be measured by current imaging techniques. The intra-tumoral cellular p heterogeneity may lead to a reduction of therapeutic effects of radiation. The purpose of this study was to investigate the effects of the heterogeneity on biological effectiveness of H-, He-, C-, O-, and Ne-ion beams for different oxygenation levels, prescribed dose levels, and cell types. Approach. The intra-tumoral cellular p distributions were simulated with a numerical tumor model for average oxygen pressures p ¯ t ranging from 2.5 to 15 mmHg. The relative biological effectiveness (RBE)-weighted dose distributions of 3–15 Gy prescribed doses were planned for a cuboid target with the five ion species for constant p ¯ t values. Radiosensitivities of human salivary gland tumor (HSG) and Chinese hamster ovary (CHO) cells were investigated. The planned dose distributions were then recalculated by taking the p heterogeneity into account. Main results. As p ¯ t decreased and prescribed dose increased, the biological effectiveness of the ion beams decreased due to the p heterogeneity. The reduction in biological effectiveness was pronounced for lighter H- and He-ion beams compared to heavier C-, O-, and Ne-ion beams. The RBE-weighted dose in the target for HSG (CHO) cells decreased by 41.2% (44.3%) for the H-ion beam, while it decreased by 16.7% (14.7%) for the Ne-ion beam at a prescribed dose of 15 Gy under a p ¯ t of 2.5 mmHg. Significance. The intra-tumoral cellular p heterogeneity causes a significant reduction in biological effectiveness of ion beams. These effects should be considered in estimation of therapeutic outcomes.
- 20 May 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (11) , 115017
Biological dose optimization incorporating intra-tumoural cellular radiosensitivity heterogeneity in ion-beam therapy treatment planning
Objective. Treatment plans of ion-beam therapy have been made under an assumption that all cancer cells within a tumour equally respond to a given radiation dose. However, an intra-tumoural cellular radiosensitivity heterogeneity clearly exists, and it may lead to an overestimation of therapeutic effects of the radiation. The purpose of this study is to develop a biological model that can incorporate the radiosensitivity heterogeneity into biological optimization for ion-beam therapy treatment planning. Approach. The radiosensitivity heterogeneity was modeled as the variability of a cell-line specific parameter in the microdosimetric kinetic model following the gamma distribution. To validate the developed intra-tumoural-radiosensitivity-heterogeneity-incorporated microdosimetric kinetic (HMK) model, a treatment plan with H-ion beams was made for a chordoma case, assuming a radiosensitivity heterogeneous region within the tumour. To investigate the effects of the radiosensitivity heterogeneity on the biological effectiveness of H-, He-, C-, O-, and Ne-ion beams, the relative biological effectiveness (RBE)-weighted dose distributions were planned for a cuboid target with the stated ion beams without considering the heterogeneity. The planned dose distributions were then recalculated by taking the heterogeneity into account. Main results . The cell survival fraction and corresponding RBE-weighted dose were formulated based on the HMK model. The first derivative of the RBE-weighted dose distribution was also derived, which is needed for fast biological optimization. For the patient plan, the biological optimization increased the dose to the radiosensitivity heterogeneous region to compensate for the heterogeneity-induced reduction in biological effectiveness of the H-ion beams. The reduction in biological effectiveness due to the heterogeneity was pronounced for low linear energy transfer (LET) beams but moderate for high-LET beams. The RBE-weighted dose in the cuboid target decreased by 7.6% for the H-ion beam, while it decreased by just 1.4% for the Ne-ion beam. Significance. Optimal treatment plans that consider intra-tumoural cellular radiosensitivity heterogeneity can be devised using the HMK model.
- 20 May 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (11) , 115017
Biological dose optimization incorporating intra-tumoural cellular radiosensitivity heterogeneity in ion-beam therapy treatment planning
Objective. Treatment plans of ion-beam therapy have been made under an assumption that all cancer cells within a tumour equally respond to a given radiation dose. However, an intra-tumoural cellular radiosensitivity heterogeneity clearly exists, and it may lead to an overestimation of therapeutic effects of the radiation. The purpose of this study is to develop a biological model that can incorporate the radiosensitivity heterogeneity into biological optimization for ion-beam therapy treatment planning. Approach. The radiosensitivity heterogeneity was modeled as the variability of a cell-line specific parameter in the microdosimetric kinetic model following the gamma distribution. To validate the developed intra-tumoural-radiosensitivity-heterogeneity-incorporated microdosimetric kinetic (HMK) model, a treatment plan with H-ion beams was made for a chordoma case, assuming a radiosensitivity heterogeneous region within the tumour. To investigate the effects of the radiosensitivity heterogeneity on the biological effectiveness of H-, He-, C-, O-, and Ne-ion beams, the relative biological effectiveness (RBE)-weighted dose distributions were planned for a cuboid target with the stated ion beams without considering the heterogeneity. The planned dose distributions were then recalculated by taking the heterogeneity into account. Main results . The cell survival fraction and corresponding RBE-weighted dose were formulated based on the HMK model. The first derivative of the RBE-weighted dose distribution was also derived, which is needed for fast biological optimization. For the patient plan, the biological optimization increased the dose to the radiosensitivity heterogeneous region to compensate for the heterogeneity-induced reduction in biological effectiveness of the H-ion beams. The reduction in biological effectiveness due to the heterogeneity was pronounced for low linear energy transfer (LET) beams but moderate for high-LET beams. The RBE-weighted dose in the cuboid target decreased by 7.6% for the H-ion beam, while it decreased by just 1.4% for the Ne-ion beam. Significance. Optimal treatment plans that consider intra-tumoural cellular radiosensitivity heterogeneity can be devised using the HMK model.
- 3 May 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (10) , 105015
Modeling of the resensitization effect on carbon-ion radiotherapy for stage I non-small cell lung cancer
Objective . To investigate the effect of redistribution and reoxygenation on the 3-year tumor control probability (TCP) of patients with stage I non-small cell lung cancer (NSCLC) treated with carbon-ion radiotherapy. Approach . A meta-analysis of published clinical data of 233 NSCLC patients treated by carbon-ion radiotherapy under 18-, 9-, 4-, and single-fraction schedules was conducted. The linear-quadratic (LQ)-based cell-survival model incorporating the radiobiological 5Rs, radiosensitivity, repopulation, repair, redistribution, and reoxygenation, was developed to reproduce the clinical TCP data. Redistribution and reoxygenation were regarded together as a single phenomenon and termed ‘resensitization’ in the model. The optimum interval time between fractions was investigated for each fraction schedule using the determined model parameters. Main results. The clinical TCP data for 18-, 9-, and 4-fraction schedules were reasonably reproduced by the model without the resensitization effect, whereas its incorporation was essential to reproduce the TCP data for all fraction schedules including the single fraction. The curative dose for the single-fraction schedule was estimated to be 49.0 Gy (RBE), which corresponds to the clinically adopted dose prescription of 50.0 Gy (RBE). For 18-, 9-, and 4-fraction schedules, a 2-to-3-day interval is required to maximize the resensitization effect during the time interval. In contrast, the single-fraction schedule cannot benefit from the resensitization effect, and the shorter treatment time is preferable to reduce the effect of sub-lethal damage repair during the treatment. Significance. The LQ-based cell-survival model incorporating the radiobiological 5Rs was developed and used to evaluate the effect of the resensitization on clinical results of NSCLC patients treated with hypo-fractionated carbon-ion radiotherapy. The incorporation of the resensitization into the cell-survival model improves the reproducibility to the clinical TCP data. A shorter treatment time is preferable in the single-fraction schedule, while a 2-to-3-day interval between fractions is preferable in the multi-fraction schedules for effective treatments.
- 3 May 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (10) , 105015
Modeling of the resensitization effect on carbon-ion radiotherapy for stage I non-small cell lung cancer
Objective . To investigate the effect of redistribution and reoxygenation on the 3-year tumor control probability (TCP) of patients with stage I non-small cell lung cancer (NSCLC) treated with carbon-ion radiotherapy. Approach . A meta-analysis of published clinical data of 233 NSCLC patients treated by carbon-ion radiotherapy under 18-, 9-, 4-, and single-fraction schedules was conducted. The linear-quadratic (LQ)-based cell-survival model incorporating the radiobiological 5Rs, radiosensitivity, repopulation, repair, redistribution, and reoxygenation, was developed to reproduce the clinical TCP data. Redistribution and reoxygenation were regarded together as a single phenomenon and termed ‘resensitization’ in the model. The optimum interval time between fractions was investigated for each fraction schedule using the determined model parameters. Main results. The clinical TCP data for 18-, 9-, and 4-fraction schedules were reasonably reproduced by the model without the resensitization effect, whereas its incorporation was essential to reproduce the TCP data for all fraction schedules including the single fraction. The curative dose for the single-fraction schedule was estimated to be 49.0 Gy (RBE), which corresponds to the clinically adopted dose prescription of 50.0 Gy (RBE). For 18-, 9-, and 4-fraction schedules, a 2-to-3-day interval is required to maximize the resensitization effect during the time interval. In contrast, the single-fraction schedule cannot benefit from the resensitization effect, and the shorter treatment time is preferable to reduce the effect of sub-lethal damage repair during the treatment. Significance. The LQ-based cell-survival model incorporating the radiobiological 5Rs was developed and used to evaluate the effect of the resensitization on clinical results of NSCLC patients treated with hypo-fractionated carbon-ion radiotherapy. The incorporation of the resensitization into the cell-survival model improves the reproducibility to the clinical TCP data. A shorter treatment time is preferable in the single-fraction schedule, while a 2-to-3-day interval between fractions is preferable in the multi-fraction schedules for effective treatments.